Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly ...

The price target adjustment represents an approximately 11% upside potential for Novo Nordisk shares, according to HSBC’s analysis. HSBC cited increased market share estimates for oral semaglutide as ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Investing.com - Shares in Eli Lilly (NYSE: LLY) sank by over 11% in early U.S. trading on Thursday after a study showed that ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

The FTSE 100 slid about 0.3 per cent early doors due chiefly to a raft of blue chips moving ex-dividend. Hikma, which reported today, led the actual fallers, slipping about 8 per cent after profits ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will have to be careful not to let market hype get in the way of steady success.

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...